Wednesday, 02 August 2017 18:44

BioPharmX Corporation released phase 2b clinical data

BioPharmX Corporation, a Silicon Valley pharmaceutical company, released phase 2b clinical data showing its investigational drug BPX-01 2% reduces acne lesions by 59 percent with no drug-related adverse events – and suggesting it may also lessen lesions’ severity. BPX-01 2% topical minocycline gel was superior in reducing the number of lesions in patients with moderate-to-severe acne, compared to vehicle (59 versus 44 percent). Evaluations using a five-point investigator’s global assessment scale also showed more two-grade improvements, compared to vehicle (29.2 versus 17.6 percent). Researchers detected no minocycline in patients’ bloodstreams, except for a single outlier whose level was one tenth that of oral minocycline.

Login to post comments

Inside Aesthetics Categories

    Featured Company

    • Bio France LabBio France LabDescription:   With 25 years of successful industry experience in both skincare and retail, Claudio DiFiore created Bio France Lab, offering superior natural and botanical luxury skincare product at an affordable cost. Combined exposure to both product develop ...

    Inside Aesthetics

    Next-Level Learning

    • Southeastern EstheticsSoutheastern EstheticsDescription: Welcome to Southeastern Esthetics Institute, a premier esthetics training institute located in the heart of South Carolina. SEEI is more than just an esthetics training program, we are a one of a kind esthetics school that offers an intimate setting and ...